|Bid||0.6856 x 0|
|Ask||0.6880 x 0|
|Day's Range||0.6570 - 0.6570|
|52 Week Range||0.6570 - 5.8500|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.14|
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 16, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.